[ad_1]
This number was obtained by estimating 16 thousand. the condition of people who have received two doses of the vaccine, according to a statement from the Russian Ministry of Health, the Gamalea State Research Center and the Russian Direct Investment Fund (RTIF).
“The effectiveness of the Sputnik V vaccine was 92% after the second dose,” the statement said, noting that 20 of the volunteers who received placebo had been tested for coronavirus infection.
The adenoviral vector vaccine was developed by modifying a common influenza virus.
Some of those vaccinated experienced “pain at the injection site, flu-like syndrome, including fever, weakness, fatigue and headache,” the developers said.
In August, Russia became the first country to register a COVID-19 vaccine, but it has taken this step without conducting large-scale clinical trials, which are still ongoing.
In the third and final test phase of Sputnik V, 40,000 people participate. volunteers vaccinated in 29 medical centers.
In September, the vaccine was administered separately to doctors and other Russian hospital personnel whose health was at risk and whose resistance to the coronavirus had reached 90 percent, according to the statement.
Authorities in Siberia’s Altai region said on Tuesday that at least three of the 42 vaccinated doctors had contracted the virus.
A statement issued Wednesday said the findings of the interim study will be published in one of the “world’s leading peer-reviewed academic medical journals.”
Participants in the clinical trial will be followed for an additional six months, followed by a full trial report.
The statement said that RTIF, which is funding the development of Sputnik V, will share research data with a country interested in the availability of Russian vaccines.
The drug is currently being tested abroad, in the United Arab Emirates, Venezuela, Belarus and other countries, the developers of Sputnik V.
These interim results were announced after Western pharmaceutical companies Pfizer and BioNTech said in recent days that their vaccine was more than 90 percent effective.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of UAB “BNS”.
[ad_2]
